Histone deacetylase inhibitors profoundly decrease proliferation of human lymphoid cancer cell lines
- 1 January 2005
- journal article
- Published by Elsevier in Experimental Hematology
- Vol. 33 (1) , 53-61
- https://doi.org/10.1016/j.exphem.2004.09.008
Abstract
No abstract availableKeywords
This publication has 27 references indexed in Scilit:
- Transcriptional signature of histone deacetylase inhibition in multiple myeloma: Biological and clinical implicationsProceedings of the National Academy of Sciences, 2003
- Gene Silencing in Cancer in Association with Promoter HypermethylationNew England Journal of Medicine, 2003
- Molecular sequelae of histone deacetylase inhibition in human malignant B cellsBlood, 2003
- The Interaction of Histone Deacetylase Inhibitors and DNA Methyltransferase Inhibitors in the Treatment of Human Cancer CellsCurrent Medicinal Chemistry - Anti-Cancer Agents, 2003
- Epigenomics and epigenetic therapy of cancerTrends in Molecular Medicine, 2002
- Histone deacetylase inhibitors as new cancer drugsCurrent Opinion in Oncology, 2001
- Reversal of methylation-mediated repression with short-chain fatty acids: evidence for an additional mechanism to histone deacetylationNucleic Acids Research, 2001
- Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitorsNature, 1999
- Epidemiology of leukemia and lymphomaCurrent Opinion in Hematology, 1999
- Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancerNature Genetics, 1999